{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T20:38:41Z","timestamp":1772138321536,"version":"3.50.1"},"reference-count":46,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,3,21]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Glycogen-synthase kinase 3 (GSK3) is a kinase mediating phosphorylation on serine and threonine amino acid residues of several target molecules. The enzyme is involved in the regulation of many cellular processes and aberrant activity of GSK3 has been linked to several disease conditions such as fragile X syndrome (FXS). Recent evidences demonstrating an increased activity of GSK3 in murine models of FXS, suggest that dysregulation\/hyperactivation of the GSK3 path should contribute to FXS development. A likely possibility could be that in FXS there is a functional impairment of the upstream inhibitory input over GSK3 thus making overactive the kinase. Since GSK3 signaling is a central regulatory node for critical neurodevelopmental pathways, understanding the contribution of GSK3 dysregulation to FXS, may provide novel targets for therapeutic interventions for this disease. In this study we used AF3581, a potent GSK3 inhibitor that we recently discovered, in an in vivo FXS mouse model to elucidate the crucial role of GSK3 in specific behavioral patterns (locomotor activity, sensorimotor gating and social behavior) associated with this disease. All the behavioral alterations manifested by Fmr1 knockout mice were reverted after a chronic treatment with our GSK3 inhibitor, confirming the importance of this pathway as a therapeutic target.<\/jats:p>","DOI":"10.1093\/hmg\/ddab251","type":"journal-article","created":{"date-parts":[[2021,9,8]],"date-time":"2021-09-08T07:28:18Z","timestamp":1631086098000},"page":"839-849","source":"Crossref","is-referenced-by-count":6,"title":["The novel potent GSK3 inhibitor AF3581 reverts fragile X syndrome phenotype"],"prefix":"10.1093","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7694-8004","authenticated-orcid":false,"given":"Pier Francesca","family":"Porceddu","sequence":"first","affiliation":[{"name":"D3 Validation Research Line, Istituto Italiano di Tecnologia, Via Morego 30, 16163 Genova, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariasole","family":"Ciampoli","sequence":"additional","affiliation":[{"name":"D3 Validation Research Line, Istituto Italiano di Tecnologia, Via Morego 30, 16163 Genova, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisa","family":"Romeo","sequence":"additional","affiliation":[{"name":"D3 Validation Research Line, Istituto Italiano di Tecnologia, Via Morego 30, 16163 Genova, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beatrice","family":"Garrone","sequence":"additional","affiliation":[{"name":"Angelini Pharma S.p.A., Viale Amelia 70, 00181 Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucia","family":"Durando","sequence":"additional","affiliation":[{"name":"Angelini Pharma S.p.A., Viale Amelia 70, 00181 Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudio","family":"Milanese","sequence":"additional","affiliation":[{"name":"Angelini Pharma S.p.A., Viale Amelia 70, 00181 Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco Paolo","family":"Di Giorgio","sequence":"additional","affiliation":[{"name":"Angelini Pharma S.p.A., Viale Amelia 70, 00181 Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angelo","family":"Reggiani","sequence":"additional","affiliation":[{"name":"D3 Validation Research Line, Istituto Italiano di Tecnologia, Via Morego 30, 16163 Genova, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2021,10,1]]},"reference":[{"key":"2022032516094066200_ref1","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/0092-8674(91)90125-I","article-title":"Absence of expression of the FMR-1 gene in fragile X syndrome","volume":"66","author":"Pieretti","year":"1991","journal-title":"Cell"},{"key":"2022032516094066200_ref2","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1038\/nrn1667","article-title":"From mRNP trafficking to spine dysmorphogenesis: the roots of fragile X syndrome","volume":"6","author":"Bagni","year":"2005","journal-title":"Nat. Rev. Neurosci."},{"key":"2022032516094066200_ref3","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1038\/s41419-021-03776-8","article-title":"Novel fragile X syndrome 2D and 3D brain models based on human isogenic FMRP-KO iPSCs","volume":"12","author":"Brighi","year":"2021","journal-title":"Cell Death Dis."},{"key":"2022032516094066200_ref4","doi-asserted-by":"crossref","first-page":"e1000898","DOI":"10.1371\/journal.pgen.1000898","article-title":"Fragile x mental retardation protein regulates proliferation and differentiation of adult neural stem\/progenitor cells","volume":"6","author":"Luo","year":"2010","journal-title":"PLoS Genet."},{"key":"2022032516094066200_ref5","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1042\/bst0070459","article-title":"The hormonal control of glycogen metabolism in mammalian muscle by multivalent phosphorylation","volume":"7","author":"Cohen","year":"1979","journal-title":"Biochem. Soc. Trans."},{"key":"2022032516094066200_ref6","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1038\/35096075","article-title":"The renaissance of GSK3","volume":"2","author":"Cohen","year":"2001","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"2022032516094066200_ref7","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/j.devcel.2007.04.001","article-title":"Functional redundancy of GSK-3alpha and GSK-3beta in Wnt\/beta-catenin signaling shown by using an allelic series of embryonic stem cell lines","volume":"12","author":"Doble","year":"2007","journal-title":"Dev. Cell"},{"key":"2022032516094066200_ref8","doi-asserted-by":"crossref","first-page":"2431","DOI":"10.1002\/j.1460-2075.1990.tb07419.x","article-title":"Molecular cloning and expression of glycogen synthase kinase-3\/factor a","volume":"9","author":"Woodgett","year":"1990","journal-title":"EMBO J."},{"key":"2022032516094066200_ref9","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.pharmthera.2014.11.016","article-title":"Glycogen synthase kinase-3 (GSK3): regulation, actions, and diseases","volume":"148","author":"Beurel","year":"2015","journal-title":"Pharmacol. Ther."},{"key":"2022032516094066200_ref10","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1038\/nrn2870","article-title":"GSK3 signalling in neural development","volume":"11","author":"Hur","year":"2010","journal-title":"Nat. Rev. Neurosci."},{"key":"2022032516094066200_ref11","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.tibs.2009.10.002","article-title":"GSK3: a multifaceted kinase in Wnt signaling","volume":"35","author":"Wu","year":"2010","journal-title":"Trends Biochem. Sci."},{"key":"2022032516094066200_ref12","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/S0891-0618(02)00014-5","article-title":"Expression of glycogen synthase kinase-3 isoforms in mouse tissues and their transcription in the brain","volume":"23","author":"Yao","year":"2002","journal-title":"J. Chem. Neuroanat."},{"key":"2022032516094066200_ref13","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1016\/j.febslet.2011.03.025","article-title":"Selective loss of glycogen synthase kinase-3\u03b1 in birds reveals distinct roles for GSK-3 isozymes in tau phosphorylation","volume":"585","author":"Alon","year":"2011","journal-title":"FEBS Lett."},{"key":"2022032516094066200_ref14","doi-asserted-by":"crossref","first-page":"e105513","DOI":"10.15252\/embj.2020105513","article-title":"GSK3\u03b1, not GSK3\u03b2, drives hippocampal NMDAR-dependent LTD via tau-mediated spine anchoring","volume":"40","author":"Draffin","year":"2021","journal-title":"EMBO J."},{"key":"2022032516094066200_ref15","doi-asserted-by":"crossref","first-page":"663","DOI":"10.2174\/1389200219666171227203737","article-title":"Glycogen synthase kinase-3\u03b2 as a putative therapeutic target for bipolar disorder","volume":"19","author":"Dandekar","year":"2018","journal-title":"Curr. Drug Metab."},{"key":"2022032516094066200_ref16","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.2174\/1389450110607011421","article-title":"Glycogen synthase kinase-3 (GSK3) in psychiatric diseases and therapeutic interventions","volume":"7","author":"Jope","year":"2006","journal-title":"Curr. Drug Targets"},{"key":"2022032516094066200_ref17","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.neuropharm.2008.09.017","article-title":"Elevated glycogen synthase kinase-3 activity in fragile X mice: key metabolic regulator with evidence for treatment potential","volume":"56","author":"Min","year":"2009","journal-title":"Neuropharmacology"},{"key":"2022032516094066200_ref18","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.biopsych.2013.08.003","article-title":"Glycogen synthase kinase-3 inhibitors reverse deficits in long-term potentiation and cognition in fragile X mice","volume":"75","author":"Franklin","year":"2014","journal-title":"Biol. Psychiatry"},{"key":"2022032516094066200_ref19","doi-asserted-by":"crossref","first-page":"eaam8572","DOI":"10.1126\/scitranslmed.aam8572","article-title":"Selective inhibition of glycogen synthase kinase 3\u03b1 corrects pathophysiology in a mouse model of fragile X syndrome","volume":"12","author":"McCamphill","year":"2020","journal-title":"Sci. Transl. Med."},{"key":"2022032516094066200_ref20","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.1021\/acs.jcim.5b00486","article-title":"Structure-based discovery of 1H-Indazole-3-carboxamides as a novel structural class of human GSK-3 inhibitors","volume":"55","author":"Ombrato","year":"2015","journal-title":"J. Chem. Inf. Model."},{"key":"2022032516094066200_ref21","doi-asserted-by":"crossref","first-page":"8920","DOI":"10.1021\/acs.jmedchem.5b01208","article-title":"Hit optimization of 5-substituted-N-(piperidin-4-ylmethyl)-1H-indazole-3-carboxamides: potent glycogen synthase kinase-3 (GSK-3) inhibitors with in vivo activity in model of mood disorders","volume":"58","author":"Furlotti","year":"2015","journal-title":"J. Med. Chem."},{"key":"2022032516094066200_ref22","doi-asserted-by":"crossref","first-page":"110249","DOI":"10.1016\/j.biopha.2020.110249","article-title":"The mood stabilizing properties of AF3581, a novel potent GSK-3\u03b2 inhibitor","volume":"128","author":"Capurro","year":"2020","journal-title":"Biomed. Pharmacother."},{"key":"2022032516094066200_ref23","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1021\/acsmedchemlett.9b00633","article-title":"Optimization of Indazole-based GSK-3 inhibitors with mitigated hERG issue and in vivo activity in a mood disorder model","volume":"11","author":"Prati","year":"2020","journal-title":"ACS Med. Chem. Lett."},{"key":"2022032516094066200_ref24","doi-asserted-by":"crossref","first-page":"e17073","DOI":"10.1371\/journal.pone.0017073","article-title":"Genetic-background modulation of core and variable autistic-like symptoms in Fmr1 knock-out mice","volume":"6","author":"Pietropaolo","year":"2011","journal-title":"PLoS One"},{"key":"2022032516094066200_ref25","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.neuroscience.2016.01.021","article-title":"Regional brain volumes changes in adult male FMR1-KO mouse on the FVB strain","volume":"318","author":"Lai","year":"2016","journal-title":"Neuroscience"},{"key":"2022032516094066200_ref26","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1111\/j.1601-183X.2008.00452.x","article-title":"Social approach in genetically engineered mouse lines relevant to autism","volume":"8","author":"Moy","year":"2009","journal-title":"Genes Brain Behav."},{"key":"2022032516094066200_ref27","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.devcel.2009.06.016","article-title":"Wnt\/beta-catenin signaling: components, mechanisms, and diseases","volume":"17","author":"MacDonald","year":"2009","journal-title":"Dev. Cell"},{"key":"2022032516094066200_ref28","doi-asserted-by":"crossref","first-page":"32227","DOI":"10.1074\/jbc.M304001200","article-title":"Phosphorylation by glycogen synthase kinase-3 beta down-regulates notch activity, a link for notch and Wnt pathways","volume":"278","author":"Espinosa","year":"2003","journal-title":"J. Biol. Chem."},{"key":"2022032516094066200_ref29","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.pediatrneurol.2020.04.019","article-title":"A double-blind, randomized, placebo-controlled clinical study of trofinetide in the treatment of fragile X syndrome","volume":"110","author":"Berry-Kravis","year":"2020","journal-title":"Pediatr. Neurol."},{"key":"2022032516094066200_ref30","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.bcp.2009.09.023","article-title":"Lithium ameliorates altered glycogen synthase kinase-3 and behavior in a mouse model of fragile X syndrome","volume":"79","author":"Yuskaitis","year":"2010","journal-title":"Biochem. Pharmacol."},{"key":"2022032516094066200_ref31","doi-asserted-by":"crossref","first-page":"8709","DOI":"10.1523\/JNEUROSCI.2077-08.2008","article-title":"Genetic dissection of the role of catechol-O-methyltransferase in cognition and stress reactivity in mice","volume":"28","author":"Papaleo","year":"2008","journal-title":"J. Neurosci."},{"key":"2022032516094066200_ref32","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1002\/aur.168","article-title":"Modifying behavioral phenotypes in Fmr1KO mice: genetic background differences reveal autistic-like responses","volume":"4","author":"Spencer","year":"2011","journal-title":"Autism Res."},{"key":"2022032516094066200_ref33","doi-asserted-by":"crossref","first-page":"3753","DOI":"10.1007\/s10803-019-04051-8","article-title":"Social avoidance emerges in infancy and persists into adulthood in fragile X syndrome","volume":"49","author":"Roberts","year":"2019","journal-title":"J. Autism Dev. Disord."},{"key":"2022032516094066200_ref34","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.neulet.2009.02.066","article-title":"Dissociation of social and nonsocial anxiety in a mouse model of fragile X syndrome","volume":"454","author":"Liu","year":"2009","journal-title":"Neurosci. Lett."},{"key":"2022032516094066200_ref35","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s12017-015-8341-2","article-title":"NNZ-2566, a novel analog of (1-3) IGF-1, as a potential therapeutic agent for fragile X syndrome","volume":"17","author":"Deacon","year":"2015","journal-title":"NeuroMolecular Med."},{"key":"2022032516094066200_ref36","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1097\/DBP.0b013e31817dc447","article-title":"Open-label treatment trial of lithium to target the underlying defect in fragile X syndrome","volume":"29","author":"Berry-Kravis","year":"2008","journal-title":"Dev. Behav. Pediatr."},{"key":"2022032516094066200_ref37","doi-asserted-by":"crossref","first-page":"e9706","DOI":"10.1371\/journal.pone.0009706","article-title":"GSK3 influences social preference and anxiety-related behaviors during social interaction in a mouse model of fragile X syndrome and autism","volume":"5","author":"Mines","year":"2010","journal-title":"PLoS One"},{"key":"2022032516094066200_ref38","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1017\/S1461145710000520","article-title":"Lithium ameliorates phenotypic deficits in a mouse model of fragile X syndrome","volume":"14","author":"Liu","year":"2011","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"2022032516094066200_ref39","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.brainres.2010.11.032","article-title":"Pharmacological reversal of synaptic plasticity deficits in the mouse model of fragile X syndrome by group II mGluR antagonist or lithium treatment","volume":"1380","author":"Choi","year":"2011","journal-title":"Brain Res."},{"key":"2022032516094066200_ref40","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1111\/j.1600-0447.1983.tb06991.x","article-title":"Lithium and pregnancy. A cohort study on manic-depressive women","volume":"68","author":"K\u00e4ll\u00e9n","year":"1983","journal-title":"Acta Psychiatr. Scand."},{"key":"2022032516094066200_ref41","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/0741-8329(86)90020-0","article-title":"Lithium and the neonate: developmental and metabolic aspects","volume":"3","author":"Messiha","year":"1986","journal-title":"Alcohol"},{"key":"2022032516094066200_ref42","first-page":"2738","article-title":"Deletion of CTNNB1 in inhibitory circuitry contributes to autism-associated behavioral defects","volume":"25","author":"Dong","year":"2016","journal-title":"Hum. Mol. Genet."},{"key":"2022032516094066200_ref43","first-page":"446","article-title":"Rebalancing protein synthesis in fragile X syndrome","volume":"19","author":"Crunkhorn","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"key":"2022032516094066200_ref44","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/1756-6606-2-35","article-title":"Abnormalities in brain structure and behavior in GSK-3alpha mutant mice","volume":"2","author":"Kaidanovich-Beilin","year":"2009","journal-title":"Mol. Brain"},{"key":"2022032516094066200_ref45","doi-asserted-by":"crossref","first-page":"262","DOI":"10.3390\/cells10020262","article-title":"Mechanisms and therapeutic implications of GSK-3 in treating neurodegeneration","volume":"10","author":"Rippin","year":"2021","journal-title":"Cell"},{"key":"2022032516094066200_ref46","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1038\/nprot.2012.099","article-title":"Culturing pyramidal neurons from the early postnatal mouse hippocampus and cortex","volume":"7","author":"Beaudoin","year":"2012","journal-title":"Nat. Protoc."}],"container-title":["Human Molecular Genetics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/hmg\/advance-article-pdf\/doi\/10.1093\/hmg\/ddab251\/40491410\/ddab251.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/hmg\/article-pdf\/31\/6\/839\/42993519\/ddab251.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/hmg\/article-pdf\/31\/6\/839\/42993519\/ddab251.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,25]],"date-time":"2022-03-25T16:34:07Z","timestamp":1648226047000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/hmg\/article\/31\/6\/839\/6367983"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,1]]},"references-count":46,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2021,10,1]]},"published-print":{"date-parts":[[2022,3,21]]}},"URL":"https:\/\/doi.org\/10.1093\/hmg\/ddab251","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.740910078.793589105","asserted-by":"object"}]},"ISSN":["0964-6906","1460-2083"],"issn-type":[{"value":"0964-6906","type":"print"},{"value":"1460-2083","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,3,15]]},"published":{"date-parts":[[2021,10,1]]}}}